Literature DB >> 20953816

Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.

Raffaella Bosco1, Marco Rabusin, Rebecca Voltan, Claudio Celeghini, Federica Corallini, Silvano Capitani, Paola Secchiero.   

Abstract

The multi-kinase inhibitor dasatinib induced a variable but significant decrease of viability in both p53(wild-type) (EHEB, JVM-2, JVM-3) and p53(mutated) (MEC-1, MEC-2, BJAB) prolymphocytic B leukemic cells, due to a combination of cell cycle block in G1 and apoptosis. Antibody phospho-kinase array analysis revealed that dasatinib inhibited the phosphorylation of various kinases, including ERK1/2 and p38/MAPK as well as of STAT3 transcription factors, in both p53(wild-type) and p53(mutated) cells. Therefore, dasatinib might offer a novel therapeutic strategy not only for p53(wild-type), but also for p53(mutated) B malignancies that have the worst prognosis and urgently need innovative therapeutic approaches.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20953816     DOI： 10.1007/s10637-010-9564-6

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  16 in total

1.  TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells.

Authors:  P Secchiero; C Zerbinati; E Rimondi; F Corallini; D Milani; V Grill; G Forti; S Capitani; G Zauli
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

2.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

Authors:  Thorsten Zenz; Alexander Kröber; Katrin Scherer; Sonja Häbe; Andreas Bühler; Axel Benner; Tina Denzel; Dirk Winkler; Jennifer Edelmann; Carsten Schwänen; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

3.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

4.  Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.

Authors:  George D Demetri; Patricia Lo Russo; Iain R J MacPherson; Ding Wang; Jeffrey A Morgan; Valerie G Brunton; Prashni Paliwal; Shruti Agrawal; Maurizio Voi; T R Jeffry Evans
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

5.  Human immunodeficiency virus type 1 envelope glycoprotein gp120-mediated killing of human haematopoietic progenitors (CD34+ cells).

Authors:  G Zauli; M C Re; G Furlini; M Giovannini; M La Placa
Journal:  J Gen Virol       Date:  1992-02       Impact factor: 3.891

6.  CREB is a critical regulator of normal hematopoiesis and leukemogenesis.

Authors:  Jerry C Cheng; Kentaro Kinjo; Dejah R Judelson; Jenny Chang; Winston S Wu; Ingrid Schmid; Deepa B Shankar; Noriyuki Kasahara; Renata Stripecke; Ravi Bhatia; Elliot M Landaw; Kathleen M Sakamoto
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

7.  IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression.

Authors:  Alexander Sainz-Perez; Hélène Gary-Gouy; Françoise Gaudin; Ghyath Maarof; Anne Marfaing-Koka; Thierry de Revel; Ali Dalloul
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

8.  Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells.

Authors:  D Milani; M Mazzoni; P Borgatti; G Zauli; L Cantley; S Capitani
Journal:  J Biol Chem       Date:  1996-09-20       Impact factor: 5.157

9.  Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.

Authors:  Paola Secchiero; Carlotta Zerbinati; Maria Grazia di Iasio; Elisabetta Melloni; Mario Tiribelli; Vittorio Grill; Giorgio Zauli
Journal:  Curr Drug Metab       Date:  2007-05       Impact factor: 3.731

10.  Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells.

Authors:  Daniela Milani; Giorgio Zauli; Erika Rimondi; Claudio Celeghini; Sandra Marmiroli; Paola Narducci; Silvano Capitani; Paola Secchiero
Journal:  J Neurochem       Date:  2003-07       Impact factor: 5.372
View more
  3 in total

1.  Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation.

Authors:  Idun Dale Rein; Kirsti Solberg Landsverk; Francesca Micci; Sebastian Patzke; Trond Stokke
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.

Authors:  Giovanna Carrà; Cristina Panuzzo; Davide Torti; Guido Parvis; Sabrina Crivellaro; Ubaldo Familiari; Marco Volante; Deborah Morena; Marcello Francesco Lingua; Mara Brancaccio; Angelo Guerrasio; Pier Paolo Pandolfi; Giuseppe Saglio; Riccardo Taulli; Alessandro Morotti
Journal:  Oncotarget       Date:  2017-05-30

3.  Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.

Authors:  J G van Oosterwijk; M A J H van Ruler; I H Briaire-de Bruijn; B Herpers; H Gelderblom; B van de Water; J V M G Bovée
Journal:  Br J Cancer       Date:  2013-08-06       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.